Coronavirus challenge studies6 Jun 2020 00:15
The Company has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV,1 Asthma, 1 cough and 1 COPD viral challenge models. As announced in early March, Open Orphan is rapidly advancing a number of Coronavirus challenge study models and expects to be helping many COVID-19 vaccine development companies to test their vaccines. No other company in the world has such a portfolio, with only two competitors globally having 1 challenge study model each.
CF is expecting 12 COVID-19 vaccine development companies to require testing of their vaccines, potentially running 3 simultaneously.
There's so much potential in this company. Next news Monday hopefully.